| IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves N Liu, Y Zhou, JJ Lee BMC medical research methodology 21 (1), 111, 2021 | 411 | 2021 |
| Resource-based destination competitiveness evaluation using a hybrid analytic hierarchy process (AHP): The case study of West Virginia Y Zhou, K Maumbe, J Deng, SW Selin Tourism Management Perspectives 15, 72-80, 2015 | 153 | 2015 |
| BOIN12: Bayesian optimal interval phase I/II trial design for utility-based dose finding in immunotherapy and targeted therapies R Lin, Y Zhou, F Yan, D Li, Y Yuan JCO precision oncology 4, 1393-1402, 2020 | 109 | 2020 |
| A utility‐based Bayesian optimal interval (U‐BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies Y Zhou, JJ Lee, Y Yuan Statistics in Medicine 38 (28), 5299-5316, 2019 | 91 | 2019 |
| TITE‐BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late‐onset toxicity and efficacy Y Zhou, R Lin, JJ Lee, D Li, L Wang, R Li, Y Yuan Statistics in medicine 41 (11), 1918-1931, 2022 | 36 | 2022 |
| Keyboard design for phase I drug-combination trials H Pan, R Lin, Y Zhou, Y Yuan Contemporary Clinical Trials 92, 105972, 2020 | 32 | 2020 |
| Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2-advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome … K Kalinsky, G Bianchini, EP Hamilton, SL Graff, KH Park, R Jeselsohn, ... Journal of Clinical Oncology 42 (17_suppl), LBA1001-LBA1001, 2024 | 30 | 2024 |
| BOIN: an R package for designing single-agent and drug-combination dose-finding trials using Bayesian optimal interval designs F Yan, L Zhang, Y Zhou, H Pan, S Liu, Y Yuan Journal of Statistical Software 94, 1-32, 2020 | 25 | 2020 |
| Incorporating historical information to improve phase I clinical trials Y Zhou, JJ Lee, S Wang, S Bailey, Y Yuan Pharmaceutical statistics 20 (6), 1017-1034, 2021 | 18 | 2021 |
| BOIN suite: A software platform to design and implement novel early-phase clinical trials Y Zhou, R Lin, YW Kuo, JJ Lee, Y Yuan JCO Clinical Cancer Informatics 5, 91-101, 2021 | 18 | 2021 |
| postMONARCH: A phase 3 study of abemaciclib plus fulvestrant versus placebo plus fulvestrant in patients with HR+, HER2-, metastatic breast cancer following progression on a … K Kalinsky, RM Layman, PA Kaufman, SL Graff, G Bianchini, M Martin, ... Journal of Clinical Oncology 40 (16_suppl), TPS1117-TPS1117, 2022 | 15 | 2022 |
| A phase II trial of alisertib (MLN8237) in salvage malignant mesothelioma CM Gay, Y Zhou, JJ Lee, XM Tang, W Lu, II Wistuba, R Ferrarotto, ... The Oncologist 25 (10), e1457-e1463, 2020 | 12 | 2020 |
| A comparative study of Bayesian optimal interval (BOIN) design with interval 3+ 3 (i3+ 3) design for phase I oncology dose-finding trials Y Zhou, R Li, F Yan, JJ Lee, Y Yuan Statistics in biopharmaceutical research 13 (2), 147-155, 2021 | 11 | 2021 |
| Early Phase Clinical Trials Y Yuan, Y Zhou, JJ Lee Principles of Clinical Cancer Research, 2018 | 5* | 2018 |
| Phase I Cancer Clinical Trial Design: Single and Combination Agents Y Yuan, Z Heng, Y Zhou Biopharmaceutical Applied Statistics Symposium 1, 204-234, 2018 | 4 | 2018 |
| The use of local and nonlocal priors in Bayesian test‐based monitoring for single‐arm phase II clinical trials Y Zhou, R Lin, JJ Lee Pharmaceutical statistics 20 (6), 1183-1199, 2021 | 3 | 2021 |
| AIDE: Adaptive intrapatient dose escalation designs to accelerate Phase I clinical trials Y Zhou, Y Zhao, G Cicconetti, Y Mu, Y Yuan, L Wang, S Penugonda, ... Pharmaceutical statistics 22 (2), 300-311, 2023 | 2 | 2023 |
| Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial K Kalinsky, G Bianchini, E Hamilton, SL Graff, KH Park, R Jeselsohn, ... Journal of Clinical Oncology, JCO-24-02086, 2024 | | 2024 |
| Recommended phase 2 dose (RP2D) for abemaciclib in combination with irinotecan (IRN) and temozolomide (TMZ) in pediatric patients with relapsed/refractory solid tumors (JPCS … Á Lassaletta, L Moreno, C Ogawa, A Ruggiero, LM Hoffman, C Pitou, ... Journal of Clinical Oncology 41 (16_suppl), 10039-10039, 2023 | | 2023 |
| Phase 1b/2 study of abemaciclib combined with chemoimmunotherapy in pediatric and young adult patients with relapsed/refractory neuroblastoma (JPCS Part C). EG Greengard, M Bear, B DeNardo, N Federman, J Krystal, ... Journal of Clinical Oncology 41 (16_suppl), TPS10068-TPS10068, 2023 | | 2023 |
Ruitao LinThe University of Texas MD Anderson Cancer CenterAdresse e-mail validée de mdanderson.org